Skip to main content


Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism

Fig. 2

Change in body weight (a) and fasting glucose (b) in db/db mice and nondiabetic mice that were administered liraglutide for 7 weeks starting at age 7 weeks. *P < 0.05 versus control db/db or WT mice (n = 8–12 in each group). WT-Saline wild-type (nondiabetic) mice treated with saline, WT-LIRA wild-type (nondiabetic) mice treated with liraglutide, db/db-Saline db/db mice treated with saline, db/db-LIRA db/db mice treated with liraglutide

Back to article page